Action 1061 ESSEX BIO-TECHNOLOGY LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Essex Bio-Technology Limited

Actions

1061

KYG312371035

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:17 07/05/2024 		Varia. 5j. Varia. 1 janv.
2,48 HKD -0,80% Graphique intraday de Essex Bio-Technology Limited +10,71% -0,40%
18/03 Essex Bio-Technology Limited annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
2023 Essex Bio-Technology Limited annonce ses résultats pour le semestre clos le 30 juin 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index
Essex Bio-Technology's Profit Jumps 22% in H1
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.
Essex Bio-Technology Limited Announces Director Changes
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.
Essex and Osteopore Entered into Exclusive Distribution Agreement
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 1061
  4. Actualités Essex Bio-Technology Limited
  5. Autres langues